Physician profile
Mary E Clark
NPI 1215435086
$3,621.45
in general payments reported to CMS, 2019-2025
22 companies · $83.48 in 2025
The $83.48 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $2,022 · 2023: $655 · 2024: $190 · 2025: $83.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,153.50 | 2022-2024 | Interstim |
| Astellas Pharma US INC | $649.55 | 2021-2023 | Veozah, Myrbetriq |
| Axonics, INC. | $248.40 | 2021-2023 | Axonics |
| Sumitomo Pharma America, INC. | $243.92 | 2023-2024 | Gemtesa |
| Abbvie INC. | $214.25 | 2021-2023 | |
| Convatec INC. | $205.33 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $171.69 | 2024-2025 | Lifevest |
| Urovant Sciences INC | $162.00 | 2021-2022 | |
| Rochester Medical Corporation | $136.49 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $113.87 | 2021-2023 | Xiaflex |
| Boston Scientific Corporation | $54.67 | 2021-2022 | |
| Myovant Sciences INC. | $38.05 | 2021-2022 | |
| Teleflex LLC | $34.56 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $33.85 | 2022-2023 | Pylarify |
| Genzyme Corporation | $32.09 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $30.27 | 2022 | |
| Halozyme INC | $19.78 | 2023 | |
| Clarus Therapeutics INC. | $17.48 | 2021 | |
| Pfizer INC. | $17.11 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.37 | 2023 | Xarelto |
| Coloplast Corp | $15.17 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.